|
KMID : 0614620070500030157
|
|
Korean Journal of Gastroenterology
2007 Volume.50 No. 3 p.157 ~ p.163
|
|
|
Docetaxel-Cisplatin-5-FU Combination Chemotherapy as a First-Line Treatment in Patients with Metastatic or Recurred Gastric Cancer
|
|
Kang Sun-Hyung
Sung Jae-Kyu
Kim Seok-Hyun
Kwon Dae-Soon
Nam Kwan-Woo
Kim Jung-Il
Kang Hyun-Mo
Kang Yoon-Sae
Goh Pyung-Gohn
Hwang Se-Woong
Moon Hee-Seok
|
|
|
Abstract
|
|
|
Purpose: The purpose of this study was to investigate the efficacy and safety of ‘docetaxel-5-FU-cisplatin’
combination chemotherapy as a first-line treatment in patients with metastatic or recurrent gastric cancer.
Methods: We investigated a total of 51 patients who were diagnosed as pathologically proven gastric cancer and
received ‘docetaxel-5-FU-cisplatin’ combination chemotherapy between March 2001 and March 2006. All the cases
were surgically unresectable because they were either metastatic or recurred gastric cancer. We studied these cases
retrospectively on the basis of medical records. The administered doses of decetaxel was 75 mg/m2 and cisplatin
60 mg/m2 on day 1, 5-FU 750 mg/m2 over 24 hrs on day 1 to day 5, every 4 weeks.
Results: Among the 51patients, 21 patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 27 patients had PS 1, 3 patients had PS 2. For response rates, 7 (13.7%) achieved complete response, 17 (33.3%) partial response, 12 (23.5%) stable disease, and 15 (29.4%) progressive disease, respectively. The overall response rate was 47.1%. The median time to progression was 6.7 months (2-34 months). Median overall survival was 14.6 months
(2.7-62.5 months). Median disease free survival was 9.5 months (4.2-21.9 months). National Cancer Institute-common
toxicity criteria (NCI-CTC) grade 4 leukopenia occurred in 10 cases (per 229 cycles). Grade 4 neutropenia occurred in 51 cases, grade 4 thrombocytopenia in 2 cases. Grade 1 mucositis occurred in 32 cases, grade 1myalgia in 6 cases.
Conclusion: ‘docetaxel-5-FU-cisplatin’ combination chemotherapy is an active and tolerable regimen as a first-line treatment in patients with metastatic or recurred gastric cancer. (Korean J Gastroenterol 2007;50:157-163)
|
|
|
KEYWORD
|
|
|
Gastric cancer, Docetaxel, Cisplatin, 5-FU, Chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|
|